Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis

Sustained efficacy was confirmed with an annualized relapse rate of 0.098 and 67% of patients were relapse-free at six years


Safety was consistent with prior findings and the established safety...

Related Keywords

West Palm Beach ,Florida ,United States ,Jennifer Hadlock ,Damemarie Paul ,John Deluca ,Bristol Myers Squibb ,Bruce Cree ,Krzysztof Selmaj ,Hans Peter Hartung ,Jonathan Sadeh ,Diego Centonze ,Exchange Commission ,Weill Institute For Neurosciences ,Research In Multiple Sclerosis ,Facebook ,University Of California San Francisco ,Twitter ,Ucsf Ms Center ,Instagram ,Americas Committee For Treatment ,Youtube ,Clinical Research ,Linkedin ,Americas Committee ,Multiple Sclerosis ,Clinical Neurology ,California San Francisco ,Weill Institute ,Clinical Research Director ,Bristol Myers ,Myers Squibb ,Ralf Gold ,Sarah Morrow ,Delivering Breakthrough Science ,Meaningful Interventions ,Multifocal Leukoencephalopathy ,Atrioventricular Conduction Delays ,Blood Pressure ,Reversible Encephalopathy Syndrome ,Immune Modulating Drugs ,Disability After Stopping ,Common Adverse Reactions ,Specific Populations ,Hepatic Impairment ,Prescribing Information ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Current Reports ,